AZTA — Azenta, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

30.13

+0.25+0.84%

Overview Short InterestFilings

AZTAQT46Azenta, Inc.·NASDAQ

Overview Short InterestFilings

30.13+0.84%

Filing

Up 0.8% — Filed an 8-K material-event report (2026-08-04) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Insider open-market buyHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

KMTS+8.09%$25.93 BLFS+1.15%$32.52 STAA-0.90%$24.12 QDEL-0.73%$17.58 ATRC+0.72%$39.00 LMAT+2.09%$105.78 PLSE+1.17%$38.17 XRAY+0.99%$14.27

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.96	Insider Own	6.88%	Shs Outstand	46.09M	Perf Week	4.15%

Market Cap	1.39B	Forward P/E	49.08	EPS next Y	0.61	Insider Trans	0.33%	Shs Float	40.60M	Perf Month	17.37%

Enterprise Value	1.06B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	14.86%	Perf Quarter	23.84%

Income	-178.00M	P/S	2.33	EPS this Y	109.77%	Inst Trans	-	Short Ratio	5.62	Perf Half Y	-19.72%

Sales	597.00M	P/B	0.89	EPS next Y	58.62%	ROA	-9.36%	Short Interest	6.03M	Perf YTD	-9.41%

Book/sh	33.74	P/C	3.65	EPS next 5Y	46.03%	ROE	-10.69%	52W High	41.73 -27.80%	Perf Year	-6.83%

Cash/sh	8.27	P/FCF	45.15	EPS past 3/5Y	-	ROIC	-0.70%	52W Low	15.93 89.14%	Perf 3Y	-35.84%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	2.29% 8.83%	Gross Margin	44.55%	Volatility	4.97% 4.47%	Perf 5Y	-65.28%

Dividend TTM	-	EV/Sales	1.78	EPS Y/Y TTM	-28.16%	Oper. Margin	-2.62%	ATR (14)	1.25	Perf 10Y	138.37%

Dividend Ex-Date	Dec 02, 2021	Quick Ratio	2.52	Sales Y/Y TTM	4.19%	Profit Margin	-29.86%	RSI (14)	69.09	Recom	2.42

Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	2.83	EPS Q/Q	12.50%	SMA20	10.79%	Beta	1.37	Target Price	45.00

Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	1.40%	SMA50	21.02%	Rel Volume	0.85	Prev Close	29.88

Employees	2,900	LT Debt/Eq	0.06	Earnings	Nov 17	SMA200	7.50%	Avg Volume	1.04M	Price	30.13

IPO Date	Feb 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	-34.83% 1.06%	Net Debt/EBITDA	1.92	Volume	886,729	Change	0.84%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-05-26	Reiterated	Evercore ISI Group	Outperform	$50 → $45
Jan-05-26	Upgrade	Evercore ISI Group	In Line → Outperform	$33 → $50
Dec-19-25	Reiterated	Needham	Buy	$78 → $44
Nov-25-25	Reiterated	Raymond James	Outperform	$45
Oct-30-25	Upgrade	Jefferies	Hold → Buy	$64 → $38
Aug-06-25	Upgrade	Raymond James	Market Perform → Outperform
Aug-05-25	Reiterated	Evercore ISI Group	In Line	$62 → $33
Dec-18-24	Upgrade	Stephens & Co.	Equal Weight → Overweight
Apr-04-24	Reiterated	Jefferies		$64
May-10-23	Downgrade	Keybanc	Overweight → Sector Weight

Latest News

Aug-04-26

Aug-04-2604:30PM

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.prnewswire.com

Jul-29-26

Jul-29-2604:35AM

Conestoga Small Cap Composite Q2 2026 Portfolio ActivitySeekingAlpha

Jul-28-26

Jul-28-2603:50AM

American Capital Management Inc. Acquires 274,588 Shares of Azenta, Inc. $AZTAdefenseworld.net

Jul-22-26

Jul-22-2604:05PM

Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcastprnewswire.com

Jul-08-26

Jul-08-2608:00AM

Azenta Completes Sale of B Medical Systemsprnewswire.com

Company

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 9/30/2025	FY 2024 9/30/2024	FY 2023 9/30/2023	FY 2022 9/30/2022	FY 2021 9/30/2021	FY 2020 9/30/2020	FY 2019 9/30/2019	FY 2018 9/30/2018
Total Revenue	597	594	573	665	555	514	389	781	632
Cost of Goods Sold Incl. D&A	331	324	319	432	325	299	244	489	405
Gross Profit	266	270	255	233	231	215	145	292	227
Selling, General and Administrative Excl. Other	247	251	253	281	227	189	156	181	145
Research and Development	33	30	32	34	28	22	16	56	47
Other Operating Expense	1	1	0	0	0	0	0	0	0
Operating Income	-15	-11	-30	-82	-24	4	-28	55	34
Interest Expense	0	0	0	0	5	2	3	22	10
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-134	4	11	52	19	-51	-10	-23	-4
Net Income Before Taxes	-150	-7	-19	-30	-10	-49	-40	9	20
Income Taxes	-39	-32	5	-18	1	-20	-14	0	-47
Consolidated Net Income	-178	-56	-165	-14	-429	111	65	29	117
Net Income From Continuing Operations	-109	24	-24	-13	-11	-29	-26	10	68
Net Income	-178	-56	-165	-14	-429	111	65	29	117
EPS (Recurring)	-3.95	-1.22	-3.09	-0.22	-0.15	-0.39	0.88	0.14	1.65
EPS (Basic, Before Extraordinaries)	-3.95	-1.22	-3.09	-0.22	-0.15	-0.39	0.88	0.14	1.65
EPS (Diluted)	-3.96	-1.22	-3.09	-0.22	-0.15	-0.39	0.88	0.14	1.64
EBITDA	-92	54	72	55	48	10	28	86	67
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	52.57	264.50	21.36
Price To Sales Ratio	2.32	2.22	4.48	4.98	5.79	14.74	8.80	3.41	3.88
Gross Margin	44.56	45.45	44.50	35.04	41.62	41.83	37.28	37.39	35.92
Operating Margin	-2.51	-1.85	-5.24	-12.33	-4.32	0.78	-7.20	7.04	5.38
Net Margin	-29.82	-9.43	-28.80	-2.11	-77.30	21.60	16.71	3.71	18.51
Shares Outstanding	46	46	53	66	75	74	74	72	70
Market Capitalization	1,386	1,321	2,567	3,313	3,215	7,574	3,423	2,666	2,452
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Starr Ephraim	SVP, Gen Counsel & Secretary	Jul 31 '26	Buy	24.17	335	8,096	68,728	Aug 04
Cornog William L	Director	May 18 '26	Buy	16.38	10,000	163,800	19,703	May 19
Cornog William L	Director	May 20 '25	Buy	27.37	2,748	75,213	25,795	Nov 25
Cornog William L	Director	May 19 '25	Buy	26.98	4,152	112,021	23,047	Nov 25
Cornog William L	Director	May 16 '25	Buy	26.50	100	2,650	18,895	Nov 25
Pirogova Olga	SVP and CHRO	Aug 12 '25	Sale	28.54	1,085	30,966	18,288	Nov 14
Zhou Ginger	SVP and GM, Multiomics	Aug 12 '25	Sale	28.54	1,085	30,966	26,831	Nov 14
Marotta John	President and CEO	Jun 02 '25	Buy	25.99	1,000	25,990	107,296	Nov 14
Malus Alan J	Director	May 30 '25	Buy	26.65	12,000	319,800	17,035	Nov 14
Marotta John	President and CEO	Sep 10 '25	Sale	29.41	316	9,294	105,980	Sep 12
Lin Lawrence Y.	EVP, CFO and Treasurer	Aug 11 '25	Buy	27.96	2,500	69,900	46,013	Aug 12
Hughes Violetta	VP, Chief Accounting Officer	Feb 03 '25	Sale	52.97	317	16,791	9,603	Feb 04
Zhou Ginger	SVP and General Manager, Genom	Jan 31 '25	Buy	45.88	417	19,132	27,916	Feb 04
Joseph Jason	SVP, General Counsel, Secy.	Nov 19 '24	Sale	40.07	1,139	45,640	112,564	Nov 21
Cueto Herman	EVP, Chief Financial Officer	Nov 19 '24	Sale	40.07	712	28,530	23,892	Nov 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.